Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The University of Texas Health Science Center, Houston
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
HIV-1 infection, documented by any licensed HIV test
Male subjects ≥ 18 years of age
Identify as MSM (men who have sex with men)
Currently on continuous ART for ≥24 weeks prior to study entry with no change in the ART regimen within the 12 weeks prior to study
Ability and willingness of the participating subject to sign the informed consent form
No plan to change ART regimen for the study duration
Screening CD4+ cell count \>350 cells/mm3 obtained within 45 days prior to study entry
HIV RNA \< 20 copies/ml for ≥12 weeks (1 blip of \< 500 copies/ml will be permitted)
Absolute neutrophil count ≥ 1000 cells/mm3
You may not be if
Initiation of ART during acute/early HIV infection (within 6 months of HIV seroconversion)
Co-infection with Hepatitis B (positive HBsAg or positive HBcAb total with detectable HBV DNA levels) or Hepatitis C (positive HCV IgG with detectable HCV RNA levels)
Use of antibiotics 60 days prior to the study entry
Use of investigational therapies or vaccines 60 days prior to the study entry
Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry
Cirrhosis, inflammatory bowel disease, total colectomy, colon or rectal anastomosis, bowel resection, or current colostomy
Diabetes mellitus
Any episode of acute or persistent diarrhea within 60 days prior to study entry
Use of any of the following medications/products for more than 3 consecutive days within the 60 days prior to study entry: Immunosuppressives, Immune modulators, Antineoplastic agents (except for topical agents for skin cancer), Probiotics and prebiotics (supplements and products).
Clareo Health | Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV
